Lipocine Announces Tentative Approval of TLANDO SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, […]